Financial Advocates Investment Management Bluebird Bio, Inc. Transaction History

Financial Advocates Investment Management

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 07, 2023	BUY	$2.79 - $5.03 $31,945 - $57,593	11,450 New	11,450 $37,000
Q4 2022 Feb 14, 2023	SELL	$5.77 - $8.49 $175,298 - $257,934	-30,381 Reduced 67.41%	14,690 $101,000
Q3 2022 Nov 14, 2022	BUY	$3.75 - $7.39 $129,903 - $255,996	34,641 Added 332.13%	45,071 $3.54 Million
Q2 2022 Aug 12, 2022	SELL	$2.94 - $5.23 $4,116 - $7,322	-1,400 Reduced 11.83%	10,430 $43,000
Q1 2022 May 11, 2022	SELL	$4.07 - $10.6 $8,140 - $21,200	-2,000 Reduced 14.46%	11,830 $57,000
Q4 2021 Feb 14, 2022	SELL	$8.96 - $16.31 $281,379 - $512,199	-31,404 Reduced 69.43%	13,830 $138,000
Q3 2021 Nov 04, 2021	BUY	$11.24 - $21.0 $449,746 - $840,273	40,013 Added 766.39%	45,234 $1.31 Million
Q2 2021 Aug 03, 2021	SELL	$18.04 - $22.09 $483,508 - $592,056	-26,802 Reduced 83.7%	5,221 $681,000
Q1 2021 May 10, 2021	BUY	$16.59 - $33.89 $479,716 - $979,963	28,916 Added 930.67%	32,023 $1.17 Million
Q4 2020 Feb 12, 2021	BUY	$27.5 - $37.92 $85,442 - $117,817	3,107 New	3,107 $310,000

151

63.4M

264K

428K

Ticker BLUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,121,800
Market Cap $28.5M
Description
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell ...

Get notified when there are updates to the investment portfolio of Financial Advocates Investment Management, based on Form 13F filings with the SEC.

Stay updated on Financial Advocates Investment Management with notifications on news.